All noemes
Trial · NCT03887455

Noeme · dazhak89

Current
neurology

Active replication — ongoing trial, registry, or meta-analysis.

Recent follow-up analyses of CLARITY-AD (lecanemab) are confirming the original effect size in real-world data.

TL;DR · AI-generated

tldr@v2.0.0
semanticscholar.org

Lecanemab reduced markers of amyloid in early Alzheimer's disease and resulted in moderately less decline on measures of cognition and function than placebo at 18 months but was associated with adverse events.

Your position — does this noeme still stand given current evidence?

0% (impossible)

50%

100% (certain)

25
50
75

Proper-scoring-rule preview

If TRUE: Brier 0.250 · log 0.69 · +8 rep
If FALSE: Brier 0.250 · log 0.69 · -1 rep
Kelly 25.0% ≈ 250 rep

Your position is kept on this device until you sign in.

Evidence stream

2 events · 1 snapshot

posterior drift

71% → 71% (0pp · 1 point)

posterior drift: 71% → 71%
neutral

Registry data

NCT03887455

Apr 18, 2026

supports

Peer-reviewed paper

+21pp

Expert reactions · 0

Sign in to post a take, cite a related claim, or flag a methodological concern.

No reactions yet. Be the first expert to post a take, cite a related claim, or flag a methodological concern.

Source publication

Lecanemab in Early Alzheimer’s Disease

Christopher H. van Dyck et al. · New England Journal of Medicine · 2023

4.9k citations · S2 3.3k
171 influential
FWCI 530.4 · Landmark
OA · bronze
19 authors · 42% ORCID

· openalex W4310461604 · s2 d18c2765